The major histocompatibility complex class I (MHC1) molecule plays a crucial role in cytotoxic lymphocyte function. ␤2-Microglobulin (␤2m) has been demonstrated to be both a structural component of the MHC1 complex and a chaperone-like molecule for MHC1 folding. ␤2m binding to an isolated ␣3 domain of MHC1 heavy chain at micromolar concentrations has been shown to accurately model the biochemistry and thermodynamics of ␤2m-driven MHC1 folding. These results suggested a model in which the chaperone-like role of ␤2m is dependent on initial binding to the ␣3 domain interface of MHC1 with ␤2m. Such a model predicts that a mutant ␤2m molecule with an intact MHC1 ␣3 domain interaction but a defective MHC1 ␣1␣2 domain interaction would block ␤2m-driven folding of MHC1. In this study we generated such a ␤2m mutant and demonstrated that it blocks MHC1 folding by normal ␤2m at the expected micromolar concentrations. Our data support an initial interaction of ␤2m with the MHC1 ␣3 domain in MHC1 folding. In addition, the dominant negative mutant ␤2m can block T-cell functional responses to antigenic peptide and MHC1.
The major histocompatibility complex class I (MHC1) molecule plays a crucial role in cytotoxic lymphocyte function. ␤2-Microglobulin (␤2m) has been demonstrated to be both a structural component of the MHC1 complex and a chaperone-like molecule for MHC1 folding. ␤2m binding to an isolated ␣3 domain of MHC1 heavy chain at micromolar concentrations has been shown to accurately model the biochemistry and thermodynamics of ␤2m-driven MHC1 folding. These results suggested a model in which the chaperone-like role of ␤2m is dependent on initial binding to the ␣3 domain interface of MHC1 with ␤2m. Such a model predicts that a mutant ␤2m molecule with an intact MHC1 ␣3 domain interaction but a defective MHC1 ␣1␣2 domain interaction would block ␤2m-driven folding of MHC1. In this study we generated such a ␤2m mutant and demonstrated that it blocks MHC1 folding by normal ␤2m at the expected micromolar concentrations. Our data support an initial interaction of ␤2m with the MHC1 ␣3 domain in MHC1 folding. In addition, the dominant negative mutant ␤2m can block T-cell functional responses to antigenic peptide and MHC1.
The major histocompatibility complex class I (MHC1) 1 molecule and antigenic peptide are recognized by CD8ϩ cytotoxic T-lymphocytes (CTL) in CTL activation and lysis of targets (1) . The heavy chain of the MHC1 molecule can interact noncovalently with a number of other molecules in the formation of a CTL activating complex. These include the MHC1 light chain or ␤2m, the antigenic peptide fragment, the T-cell receptor (TCR), and the CD8 molecule (2) . The specificity of the CTL response resides in the selective MHC1 binding of specific antigenic peptide fragments and in the TCR recognition of these antigenic peptides and MHC1 (3, 4) . The MHC1 contact surface for TCR and peptide binding is formed by the ␣1 and ␣2 domains of the three-domain MHC1 heavy chain (2, (5) (6) (7) .
The MHC1 heavy chain ␣1 and ␣2 domains, as well as the immunoglobulin-like ␣3 domain, have been shown by x-ray crystallography (8) to interact with ␤2m, the nonpolymorphic component of the MHC1 complex. Mutations in the ␣1 (9, 10) or ␣3 (11) domains of the MHC1 heavy chain lead to changes in ␤2m binding. These studies demonstrate that the functional interaction of the MHC1 heavy chain with ␤2m occurs at multiple surfaces on different domains.
In the absence of ␤2m, most MHC1 molecules are not expressed efficiently on the surface of cells (12, 13) . Although some MHC1 molecules, such as murine H-2L
d and H-2D b , are transported to the cell surface without ␤2m, they have diminished levels of expression (14, 15) . This decreased MHC1 expression is not simply because of an export requirement for fully assembled MHC1 complexes. Transfection of ␤2m-negative cells with ER-retained ␤2m was able to salvage MHC1 cell surface expression (16) . MHC1 folded in the presence of this ER-retained ␤2m was exported to the cell surface without bound ␤2m. Thus ␤2m, which promotes protein folding through a transient interaction, fits the definition of a chaperone (17) . Therefore, ␤2m plays two roles in MHC1, first, as a structural subunit of the assembled complex and second, as a chaperone for the folding of the MHC1 heavy chain. A possible mechanism for ␤2m as a chaperone is facilitation of the interaction of MHC1 heavy chain with other chaperones, such as calreticulin, tapasin, transporter associated with antigen processing, and Erp57 (18, 19) . However, because ␤2m has been shown to promote stabilization or folding of MHC1 on the cell surface in the absence of ER chaperones (20, 21) , it is likely that ␤2m also has a direct effect on MHC1 folding.
Although high concentrations of high affinity peptides can promote the folding of MHC1 in the absence of ␤2m (15), these same peptides can stabilize MHC1 folded with ␤2m at significantly lower concentrations (22, 23) . Therefore, with physiologic concentrations of high affinity peptides or any concentration of lower affinity peptides, ␤2m levels are limiting for the folding of MHC1 molecules.
The two roles of ␤2m, as structural subunit and chaperone, do not depend equally on ␤2m concentration. ␤2m binds to MHC1 heavy chain with an equilibrium dissociation constant (K d ) in the nanomolar range (24 -27) while it folds or stabilizes cell surface MHC1 at micromolar concentrations (20, 21, 28) . We have demonstrated previously (29) that human ␤2m (h␤2m) binds the isolated ␣3 domain of the MHC1 heavy chain with a K d in that same micromolar range and this binding has the same species dependence and thermodynamics as the ␤2m-driven refolding of the MHC1 heavy chain (30) . This suggested * This work was supported by the Howard Hughes Medical Institute and Montgomery County Public Schools student intern program. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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To resolve this issue, we have generated ␤2m mutants with predicted defects in interactions with MHC1 ␣1/␣2 domains and evaluated the mutant ␤2m effects on native ␤2m-driven folding of MHC1. Because the ␤2m-driven folding of the ␣1 and ␣2 domains is likely to be dependent on the ␤2m-␣1/␣2 interaction, many possible models would predict poor folding of MHC1 by these mutants. However, if the initial limiting interaction of ␤2m were with the ␣3 domain, these ␤2m mutants would still have an intact initial interaction and be able to compete with native ␤2m for this initial interaction. Thus ␤2m mutants with diminished ␣1/␣2 interactions would be competitive inhibitors of native ␤2m-driven MHC1 folding. Although such a mutant ␤2m protein would be predicted to inhibit extracellular MHC1 folding, its design and mode of inhibition are similar to dominant negative mutations used in the study of intracellular signaling and cytoskeletal structures (31, 32) . It would be expected that this dominant negative effect on MHC1 folding would have a concentration dependence similar to that of the ␤2m-␣3 interaction.
EXPERIMENTAL PROCEDURES

␣3 Domain Protein Expression and Purification-The H-2D
d ␣3 domain sequence was generated by PCR amplification of an H-D d cDNA as described previously (29) with the upper primer ACTCCATGGCAA-CAGATCCCCCAAAGGCCC and the lower primer GATGAATTCGAC-CCGGAAGGAGGAGGTTC. The ␣3 domain sequence was inserted between the NcoI and EcoR1 sites of a modified pET21d vector (Novagen, Madison, WI). The vector was modified by ligating a synthetic oligonucleotide (GAGGAATTCTGGAATTTCGCAAGCTGTACATGCTGCA-CACGCTGAAATTAACGAAGCAGGAAGAGCACTCGAGCAC) between the EcoR1 and XhoI sites of the pET21d bacterial expression vector. The completed construct had the correct sequence and when transfected and induced, generated a 15-kDa fusion protein consisting of the H-D d ␣3 domain fused to vector expressed sequence, a 17-amino acid peptide sequence from ovalbumin, and a polyhistidine tag.
The expression construct was transfected into BL21(DE3) bacteria (Novagen, Madison, WI). 400-ml cultures of transfected bacteria in LB broth with 200 g/ml carbenicillin (Sigma) were grown to an absorbance of 0.6 at 600 nm. The cultures were then induced with 1 mM isopropyl-1-thio-␤-D-galactopyranoside (Sigma), and the cells were harvested by centrifugation after overnight induction at 28°C. The bacteria were washed with PBS, and the pellet was frozen at Ϫ70°C. The frozen pellet was thawed in 0.5 M NaCl, 10 mM Tris, pH 8.0, with 1 mg/ml lysozyme (Sigma). After addition of imidazole (Sigma) to a concentration of 5 mM and Triton X-100 (Roche Molecular Biochemicals) to a concentration of 1%, the bacteria were sonicated in a Brinkmann homogenizer (Brinkmann, Westbury, CT) for 3 ϫ 30 s at a setting of 4. The homogenate was treated with ϳ500 units of Benzonase (Sigma) in the presence of 5 mM MgCl. Inclusion bodies were pelleted by spinning at 15,000 ϫ g, and the soluble fraction was loaded on to buffer-equilibrated nickel-nitrilotriacetic acid resin (Qiagen) for 1 h at 4°C. The loaded nickel-nitrilotriacetic acid resin was washed three times with 0.5 M NaCl, 10 mM Tris, pH 8.0, 1% Triton X 100, 5 mM imidazole buffer and then three times with 0.5 M NaCl, 10 mM Tris, pH 8.0, buffer. The fusion protein was eluted with high concentration imidazole (150 to 500 mM). The imidazole was removed by dialysis, and the protein was further purified by size exclusion chromatography. The protein concentration was measured by 280-nm absorbance. The extinction coefficient at 280 nm was calculated from the primary amino acid sequence (33) .
␤2m Mutagenesis, Expression, and Purification-The recombinant native h␤2m was expressed using a construct in a PET21d vector generously supplied by Randall K. Ribaudo (34, 35) . Mutant h␤2m genes were generated by PCR with the Pfu-1 polymerase (Stratagene) using splice overlap extension (36) with mutant oligonucleotides. The D53K mutation was generated with the upper GGAGCATTCAAAATT-GTCTTTCA oligonucleotide primer (the base pairs in mutated codons are underlined) and a complementary lower primer. The D53R mutation was generated with the upper GGAGCATTCAAGATTGTCTTTCA oligonucleotide primer and a complementary lower primer. The W60A mutation was generated with the upper ATAGAAAGACGCGTCCTT-GCT oligonucleotide primer and a complementary lower primer. The h␤2m upper GACGGAGCTCGAATTCGGATC primer and h␤2m lower AGGAGATATATCATGATCCAGCGT primer were used with the corresponding mutant oligos to amplify the mutated gene fragments in the first amplification step and for generating an intact gene the second amplification step. The intact gene fragments were digested with BspHI and BamHI and ligated into PET21d vector that was digested with NcoI and BamHI. Double mutants such as W60A/D53K were sequentially generated using the same process. The mutant genes were verified by sequencing. The constructs were transfected into BL21(DE3) bacteria (Novagen). 100-ml cultures of transfected bacteria in LB broth with 250 g/ml carbenicillin with were grown at 37°C to an absorbance of 0.8 at 600 nm and then induced with 1 mM isopropyl-1-thio-␤-D-galactopyranoside for 2 h. The bacteria were harvested by centrifugation and washed and resuspended with 0.1 M Tris, pH 8.0, with 2 mM EDTA. Lysozyme (Sigma) was added at 0.5 mg/ml, and the bacteria were incubated overnight at 4°C. Deoxycholate was added to a final concentration of 0.1%, and the mixture was sonicated on a Brinkmann homogenizer for 4 ϫ 30 s. The inclusion bodies were pelleted by centrifugation at 15,000 ϫ g, and the soluble fraction was discarded. Inclusion bodies were washed three times with 0.1 M Tris, pH 8.0, with 2 mM EDTA and 0.1% deoxycholate followed by a wash with 0.1 M Tris, pH 8.0, 2 mM EDTA. The pellet was resuspended with 2 ml of 6 M guanidine HCl, 0.1 mM dithiothreitol, 0.1 M Tris, pH 8.0, 2 mM EDTA. The dissolved protein was added to 50 ml of pre-chilled 0.4 M arginine, 0.1 M Tris, 2 mM EDTA, 5 mM oxidized glutathione, 0.5 mM reduced glutathione and left to refold in the cold room with gentle agitation for a minimum of 3 days. The protein was then dialyzed against 1 liter of HEPES-buffered saline, 3 mM EDTA three times and then concentrated using an Amicon ultrafiltration cell and MicroSep 3K omega filters (Pall Corporation, Ann Arbor, MI). The concentrated ␤2m was then purified by size exclusion chromatography. Both native and mutant ␤2m were purified in the same manner. The protein concentrations were measured by 280-nm absorbance. The extinction coefficient at 280 nm was calculated from the primary amino acid sequence (33) .
Size Exclusion Chromatography-For ␤2m and for H-2D d ␣3 domain purification, 500 -1000 l of protein was loaded onto a Superdex 75 column (Pharmacia LKB, Amersham Biosciences, Uppsala, Sweden) using the P-500 pump (Pharmacia LKB) at 0.5 ml/min buffer. Half-ml fractions were collected, and the protein concentration was determined by 280-nm absorbance. Protein used for surface plasmon resonance experiments was purified in HBS-EP buffer (HEPES-buffered saline with 3 mM EDTA and 0.005% polysorbate 20) or PBS. Proteins used in flow cytometry and functional experiments were purified in PBS.
Antibodies, Cell Lines, and Peptide-Anti-tetra His antibody was purchased from Qiagen. Surface Plasmon Resonance (SPR) Experiments and Data AnalysisAll SPR experiments were performed on the BIAcore 3000 biosensor (BIAcore AB, Uppsala, Sweden). Anti-His antibody, diluted in 10 mM acetate buffer, pH 4.5, was covalently coupled to the carboxymethylated dextran matrix on a CM5 sensor chip (Biacore AB) by using the amine coupling kit as described previously (43) . Experiments were performed in HBS-EP buffer, and regeneration of the anti-His surface was achieved with 20 mM HCl.
Equilibrium binding data for ␤2m were obtained by averaging a 5-10-s interval of normalized signal after reaching equilibrium. The normalized signal was obtained by subtracting the control surface signal from ␣3 surface signal. The equilibrium binding data was analyzed by nonlinear curve fitting of the Langmuir isotherm to the data. The curve fitting was performed using the BIAevaluation 3.0 software (BIAcore AB).
Flow Cytometry ␤2m MHC1 Folding Assay-␤2m and ␤2m mutants were titrated at the indicated concentrations in 24-or 12-well tissue culture plates containing 1 or 2 ml of OPTI-MEM medium (Invitrogen) with 0.5% BSA (Sigma) and 0.5 ϫ 10 6 LKD8 cells (for H-2D d folding) or 0.5 ϫ 10 6 RMAs-K d cells (for H-2K d folding) per well. The assay was carried out in a 7.5% CO 2 incubator at 26 -28°C for low temperatureinduced folding or at 37°C, with the indicated concentration of peptide, for peptide-induced folding. After an overnight incubation, the cells were spun down at 4°C. One-half g of the biotinylated anti-H-2D d antibody, 34.5.8S (Pharmingen), or biotinylated anti-H-2K d antibody, SF1-1.1 (Pharmingen), was added to the cells. Cells receiving no primary antibody or a biotinylated isotype-matched antibody (Pharmingen) were used as controls. After an hour of incubation on ice, the cells were washed with 0.5% BSA/OPTI-MEM medium and then 50 l of streptavidin-fluorescein isothiocyanate (Pharmingen), diluted 1:50 in 0.5% BSA/OPTI-MEM, was added to the cells for an additional 30-min incubation on ice. The cells were then washed with 0.5% BSA/OPTI-MEM and analyzed on a FACScalibur (BD Biosciences) flow cytometer. The cells were size-gated, and generally 2,500 to 10,000 cells were counted for each data point. Data analysis was performed using Cell Quest Software (BD Biosciences).
Mutant ␤2m Effects on Antigen-induced T-cell Activation-␤2m and ␤2m mutants were added at the indicated concentrations to wells in 96-well round bottom tissue culture plates with 3.6 ϫ 10 5 of the APC. The p18-I10 peptide was added as indicated to wells. The final volume was 200 l/well of three parts 5% BSA/OPTI-MEM and one part PBS. After an overnight incubation at 37°C in 7.5% CO 2 , the cells were washed two times with 5% BSA/OPTI-MEM and resuspended in 150 l of Dulbecco's modified Eagle's medium with 10% fetal calf serum, 2 mM L-glutamine, nonessential amino acids, penicillin/streptomycin (100 units/ml penicillin), and 5 ϫ 10 Ϫ5 M ␤-mercaptoethanol (complete medium). Fifty l of washed APC were titrated by threes into 100 l of complete medium in 96-well flat bottom tissue culture plates as indicated. B4.2.3 T-cells were added at the indicated concentrations in 50 l of complete medium, and the plates were incubated overnight at 37°C in 7.5% CO 2 . For IL2 cytokine determinations, 25 l of culture supernatants were assayed with commercially available kits (Endogen, Boston, MA) according to the manufacturer's specifications. Horseradish peroxidase-conjugated streptavidin (Zymed Laboratories Inc., San Francisco, CA) and tetramethylbenzidine (Dako, Carpinteria, CA) were used as developers. The absorbance was read on a Bio-Rad model 3550 microplate reader (Hercules, CA) at 655 nm with background subtraction. Cytokine standards were run with each experiment. A linear fit of these IL2 standard values was used to extrapolate the scales for IL2 levels. In some experiments the cells were pulsed with 1 Ci/well of [ 3 H]thymidine (PerkinElmer Life Sciences) for 3-6 h and harvested and counted to assess growth inhibition (44) .
RESULTS
␤2m Mutations and ␤2m Mutant Binding to an MHC1 ␣3 Domain-Human and murine ␤2m are ϳ70% homologous (34) , and critical ␤2m contact residues with MHC1 heavy chain are conserved (8) . Human ␤2m is more effective than murine ␤2m at folding murine MHC1 heavy chain and at binding an MHC1 ␣3 domain (30) . Because h␤2m has a higher affinity for an MHC1 ␣3 domain than murine ␤2m, we chose to mutate h␤2m. This higher affinity for MHC1 ␣3 would predictably lower the concentration necessary to observe a mutant dominant negative effect. We limited our mutation of ␤2m residues to those that interact with the ␣1 and ␣2 interface of the MHC1 heavy chain in MHC1 crystal structures. HLA-A2 and H-2D d MHC1 crystal structures (8, 45) implicate the tryptophan at position 60 of ␤2m as a critical residue for multiple contacts between ␤2m and the ␣2 domain of the MHC1 heavy chain. Mutations of ␤2m at position 60 have also been shown to interfere with ␤2m exchange onto MHC1 (46) . To create a defect in ␤2m folding of MHC1, we mutated the tryptophan at ␤2m position 60 to an alanine residue, a non-conservative change. The HLA-A2 MHC1 crystal structure also predicts a number of interactions between the aspartate at position 53 of ␤2m and residues of the ␣1 domain of the MHC1 heavy chain. However, crystal structures of H-2D d (45, 47-49) suggest weaker interactions between the aspartate at position 53 of ␤2m and the ␣1 domain. Despite this, a previous study (34) has demonstrated that changing the negatively charged aspartate residue at position 53 to a neutral valine decreased the ability of h␤2m to fold murine MHC1 molecules, including H-2D d . Based on this study, we generated charge reversal mutants, changing position 53 of ␤2m to positively charged lysine or arginine, predicting that these mutants would have greater defects in MHC1 folding than the neutral D53V mutation. In addition, we generated a ␤2m mutant with non-conservative changes at both positions, 60 and 53. Based on amino acid sequence data, these residues are conserved across murine and human ␤2m molecules (8) . The locations of the two sites we mutated in ␤2m, as related to an example MHC1 crystal structure (50) , are illustrated in Fig. 1 .
Based on structural data, our ␤2m mutants at positions 60 and 53 are likely to be defective in their interactions with MHC1 ␣1/␣2 and not MHC1 ␣3. However, to rule out an unexpected global effect of the mutations, we verified that the mutant ␤2m-␣3 interactions were not compromised. We expressed the ␤2m proteins using constructs in bacterial expression vectors (34, 35) . Purified mutant ␤2m molecules were evaluated for binding to isolated MHC1 H-2D d ␣3 domain molecules using a biosensor for SPR (30) . Antibody to the polyhistidine tail of the ␣3 protein was directly coupled to the carboxymethylated dextran surface of a biosensor chip, allowing for the capture of ␣3 protein on this surface. ␤2m molecules were injected across the surface of the immobilized ␣3 protein, and the binding was assessed by mass-related changes in the sensor chip matrix refractive index and quantified as response units (RU). ␤2m was also injected across a control surface consisting of the directly coupled capture antibody without ␣3 protein. We injected a control protein, ovalbumin, and there was no detectable ␣3 domain binding (data not shown). This experimental system was sensitive to a 2-fold difference in affinity between human and mouse ␤2m (30) . This allowed protein concentration effects on the refractive index response to be subtracted out. An example of such an SPR experiment with the W60A/D53K double mutant ␤2m is shown in Fig. 2A . The responses of the ␣3 domain and control surfaces were normalized to each other immediately prior to the injection of the ␤2m to allow comparison of the active and control surfaces in this figure. Increasing concentrations of ␤2m were then evaluated for binding to purified monomeric ␣3 domains. The binding curves after subtraction of the control surface are shown in Fig.  2B . Equilibrium values taken from the subtracted data were used to generate the plot in Fig. 2C . This plot was fit with the nonlinear Langmuir isotherm for calculation of the equilibrium binding constant. The equilibrium constants for ␣3 binding The MHC1 heavy chain is illustrated as a black backbone frame, and the antigenic peptide is illustrated as a gray backbone frame. This figure was generated using RasMol from the Protein Data Bank structure 1HHJ (HLA A201 with a nonamer human immunodeficiency virus reverse transcriptase peptide).
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were generated in this manner from three experiments with each of the ␤2m proteins and are shown in Table I . The dissociation equilibrium constants vary from ϳ0.2-0.4 micromolar for native h␤2m, and all the ␤2m mutants we generated. This suggests that these mutations do not have global effects on ␤2m structure and do not significantly modify the interaction of ␤2m with the MHC1 ␣3 domain. Thus these mutant ␤2m molecules are useful for testing our predictions regarding MHC1 folding.
Asp-53 Mutant ␤2m-driven Folding of Cell Surface MHC1 Heavy Chain-Because our ␣3 binding data were generated with a murine ␣3 MHC1 domain, we evaluated the mutant h␤2m molecules with murine MHC1. Previous studies have demonstrated that the folding of MHC1 by ␤2m, in the absence of added MHC1 binding peptide, is much more efficient at room temperature than at 37°C (20, 21, 51) . This low temperatureinduced expression of folded MHC1 in peptide transport-deficient cells is dependent on the presence of ␤2m. To study the effects of the ␤2m mutations on MHC1 ␣1/␣2 domain folding, we added bacterially expressed ␤2m molecules to a peptide transport-deficient cell line, LKD8 (37), at room temperature. This cell line lacks stable folded H-2D d heavy chain, as demonstrated by poor binding of the ␣1/␣2 conformational epitopedependent anti-H-2D d antibody, 34.5.8S (21) . Addition of increasing amounts of native h␤2m to these cells, with an overnight incubation at 26 -28°C, leads to increasing amounts of folded cell surface H-2D d MHC1 (Fig. 3A) . The increase in folded MHC1, shown by the increased binding of 34.5.8S, is greater with the addition of native h␤2m than with the addition of the Asp-53 ␤2m mutants (Fig. 3B) (Fig. 3C) .
W60A Mutant ␤2m Molecules Have Severe Defects in MHC1 Folding and Can Act as Dominant Negatives for H-2D d Folding-Despite the profound defect of the Asp-53 charge reversal mutants in enhancing H-2K
d expression, D53K can still enhance expression of H-2K d molecules when added at concentrations above 10 M (Fig. 4A) . In experiments where Asp-53 charge reversal mutants are added together with native h␤2m, no inhibition of the h␤2m-induced H-2K d expression was observed (data not shown). We then evaluated the W60A and the W60A/D53K mutant ␤2m molecules in folding MHC1. Fig. 4A shows that ␤2m molecules with the W60A mutation are less efficient at enhancing expression of H-2K d than ␤2m molecules that only have the D53K mutation. However, some increased expression of H-2K d is still observed with the W60A mutants (Fig. 4A) , and high concentrations of the W60A mutants are unable to interfere with native ␤2m-enhanced expression of H-2K d (Fig. 4B) . We then assessed the effect of the W60A mutants on H-2D d folding. Both the W60A and W60A/D53K mutants were unable to facilitate H-2D d folding even at 20 M concentrations (Fig. 4C) . In addition to the lack of H-2D d MHC1 folding, the W60A and W60A/D53K mutants were able to inhibit H-2D d folding by native ␤2m (Fig. 4D) A, anti-polyhistidine antibody was immobilized on two surfaces of an SPR sensor chip at 2850 and 3550 RU by amide coupling. 1 M ␣3 domain (dashed line) was injected over the 2850 RU anti-polyhistidine surface, and buffer (solid line) was injected over the 3550 RU anti-polyhistidine surface for 3 min at a flow rate of 10 l/min. After a 4.5-min wait, 1 M W60A/D53K mutant ␤2m was injected over both surfaces for 90 s at a flow rate of 10 l/min. The responses of the two surfaces were normalized prior to the ␤2m injection to allow comparison of the ␤2m binding of the ␣3 domain and the control surface. B, the response of the control surface to ␤2m was subtracted from the response of the ␣3 surface to ␤2m as a measure of ␤2m-␣3 binding. The binding curves shown are at the indicated concentrations of W60A/D53K mutant ␤2m. C, averages of the equilibrium W60A/D53K mutant ␤2m-␣3 binding responses during ␤2m injection were plotted versus ␤2m concentration. These points were fit with the Langmuir isotherm to determine the K d . The 2 (average of the squared residuals) value of 0.072 suggests a good fit. Fig. 5A . Both mutants are inhibitory in the low micromolar range. Although there is some variability in the relative inhibition by the two mutants, in general the double mutant W60A/D53K is a slightly more potent inhibitor. Fig. 5B demonstrates that with the W60A/ D53K mutant, the half-maximal inhibition of MHC1 folding occurs at an approximately micromolar concentration. As described previously (30) , the binding of the W60A mutants to the H-2D d ␣3 domain by SPR has an equilibrium dissociation constant of ϳ0.3 M. This SPR-derived binding is similar to that of native h␤2m. Using analytical ultracentrifugation, native h␤2m binds ␣3 with a somewhat higher equilibrium dissociation constant of ϳ4 M (30). One possible reason for this difference is a restriction of the ␣3 His-tag tether mobility when captured by the anti-His surface in SPR experiments. Independent of the reason for this difference, the inhibitory concentrations for the dominant negative ␤2m effect are very similar to the range of ␤2m-␣3 binding suggested by biophysical methods. This provides further support for a ␤2m-␣3 rate-limiting step in MHC1 folding.
Dominant Negative ␤2m Molecules Inhibit Peptide-induced Folding of H-2D
d MHC1-So far all our studies have evaluated MHC1 folding driven by ␤2m at low temperature, in the absence of added antigenic peptide. MHC1 molecules expressed in this manner contain very few detectable peptides, as determined by peptide elution and high pressure liquid chromatography analysis (54) . Because an important physiologic role for MHC1 is presentation of antigenic peptides, we also evaluated the effect of the dominant negative ␤2m mutants on peptideinduced MHC1 folding. Induction of folded H-2D
d by the human immunodeficiency virus gp160 peptide p18-I10, and native ␤2m was evaluated in the absence or presence of dominant negative ␤2m molecules (Fig. 6 ). The folding was done at 37°C to minimize native ␤2m-induced folding in the absence of peptide (51) . Although some MHC1 folding was induced by peptide in the absence of added ␤2m (82 median fluorescent units, Fig.  6 ), the combination of ␤2m and peptide led to a striking increase in folded MHC1 (348 median fluorescent units, Fig. 8 ).
Both mutant ␤2m molecules inhibit the antigenic peptide-induced folding of H-2D d , and in this experiment the W60A/D53K mutant is more effective than the W60A mutant. Thus the dominant negative effect of these mutant ␤2m molecules applies to both low temperature and antigenic peptide-induced folding of H-2D d .
Functional Effects of Dominant Negative ␤2m on T-cell Activation-Because dominant negative ␤2m molecules were able to inhibit H-2D
d folding by the antigenic peptide p18-I10, we evaluated the ability of the W60A/D53K ␤2m mutant to inhibit T-cell activation by p18-I10 in the context of H-2D d . We utilized the B4.2.3 T-cell hybridoma (39) that is reactive with the p18-I10 peptide in the presence of H-2D d -expressing APC. The H-2D d -expressing LKD8 cells were incubated overnight with peptide and native ␤2m in the presence or absence of mutant ␤2m. After washing the LKD8 APC, the cells were titrated and evaluated for stimulation of the B4.2.3 T-cell hybridoma. Although we observed some IL2 production by the B4.2.3 cells with native ␤2m in the absence of antigenic peptide, this was increased in the presence of antigenic peptide. At low antigenic peptide concentrations, native ␤2m significantly enhanced the B4.2.3 IL2 production (0.3-2.7 ng/ml IL2, data not shown). This 
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d MHC1 Folding 5634 enhancement also occurred with higher concentrations of native h␤2m (data not shown). However the native h␤2m and 0.001 M peptide-driven IL2 production was almost completely reversed by addition of 50 M of the dominant negative W60A/ D53K ␤2m (Fig. 7A) . At higher concentrations of the p18-I10 peptide, the mutant ␤2m was unable to inhibit B4.2.3 T-cell activation (Fig. 7B) . This is not unexpected, because high concentrations of MHC1 binding peptide have been shown to form complexes with MHC1 in the absence of ␤2m (15) . Evaluation of this experiment by activation-induced growth inhibition (44) gave similar results, demonstrating mutant ␤2m reversal of growth inhibition (data not shown). This rules out a cytotoxic effect of the mutant ␤2m molecules, because they lead to increased rather than decreased proliferation. Thus, the ␤2m dominant negative inhibition of MHC1 folding can lead to inhibition of a T-cell response to antigenic peptide. This inhibition was seen with a peptide transport-deficient APC, LKD8, that primarily expresses misfolded MHC1 in the absence of exogenous ␤2m and peptide. Because APC that do not have a peptide transport defect also have misfolded MHC1 (55) , this inhibitory effect should apply more generally. In the presence of native ␤2m, H-2D d L-cell transfectants can activate B4.2.3 at low cell density with peptide or high cell density in the absence of peptide, and this activation can also be inhibited by dominant negative ␤2m (data not shown).
Because endogenous antigens are loaded onto MHC1 in the ER, it is unlikely that exogenously delivered dominant negative ␤2m would interfere with ER-based MHC1 folding and peptide loading. We attempted to evaluate this by using the cell line 15-12, an H-2D d -expressing 3T3 cell line transfected with gp160 (40) , containing the p18-I10 peptide sequence. In the presence of native ␤2m, there was a large increase in IL2 production (Fig. 7C) as observed with the exogenously loaded peptide. However the addition of W60A/D53K ␤2m did not lead to consistent inhibition of T-cell activation by 15-12 cells (Fig.  7C) . A differing role of ␤2m for endogenous and exogenous antigen is suggested by these data. Endogenous peptide-loaded MHC1 may be dependent on ␤2m for stabilization whereas exogenous peptide loading is dependent on ␤2m for MHC1 refolding. Therefore the loading of exogenous antigen is more sensitive to a dominant negative ␤2m for MHC1 folding. DISCUSSION ␤2m is both a structural component of MHC1 and a chaperone for correct folding of the MHC1 heavy chain. ␤2m binds folded MHC1 heavy chain at a thousand-fold lower concentration than that required for ␤2m-driven folding of cell surface MHC1. The ␣3 domain of the MHC1 heavy chain is folded before the other MHC1 domains, prior to associating with ␤2m (56, 57), and remains folded longest on the cell surface (21) . This makes a ␤2m interaction with the ␣3 domain an attractive model for the ␤2m-driven folding of the MHC1 heavy chain. We 
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have demonstrated previously (29) that human ␤2m binding to an isolated ␣3 domain has a dissociation affinity constant in the micromolar range similar to the concentration range in which ␤2m folds MHC1. In addition, we demonstrated that the binding of the ␣3 domain by ␤2m has a species hierarchy and a temperature dependence similar to that of the folding of MHC1 heavy chain by ␤2m (30) . These data support a model in which a ␤2m-␣3 interaction is a required intermediate in the folding of MHC1 heavy chain. Such a model would predict that a ␤2m molecule that retains the ability to interact with the ␣3 domain but is defective in its ability to interact with the ␣1/␣2 domains of MHC1 would function as a competitive inhibitor of native ␤2m with a dominant negative effect on MHC1 folding. Furthermore, the concentration dependence of the dominant negative effect would relate to the affinity of ␤2m for the ␣3 domain.
In this study we demonstrate that ␤2m molecules with mutations of critical residues in the ␤2m-␣1/␣2 interface can block native ␤2m folding of H-2D d MHC1 at concentrations similar to those allowing ␤2m interaction with the H-2D d ␣3 domain. This provides very strong evidence for a ␤2m-␣3-limiting intermediate in extracellular H-2D d MHC1 folding. In our studies, we have observed only the dominant negative effect of ␤2m mutants on the H-2D d haplotype. Although it is possible that the limiting ␤2m-␣3 step is haplotype-specific, the lack of a dominant negative effect on H-2K d MHC1 may be due to our choice of ␤2m mutants. Differential effects of ␤2m mutants on MHC1 haplotypes have been described previously (49) . Experiments using additional MHC1 haplotypes and ␤2m mutations are planned to define the generality of our observations. It is likely that dominant negative ␤2m molecules can be generated that block folding of MHC1 haplotypes other than murine H-2D d . Although the data we present are limited to extracellular MHC1 folding, the binding parameters and kinetic intermediates of ␤2m interactions are likely to play an important role in MHC1 assembly in the ER. The ␤2m interaction with the ␣3 domain can be further evaluated with other fragments of MHC1 heavy chain and whole MHC1 using SPR. The addition of MHC binding peptides and chaperone molecules such as calreticulin, tapasin, transporter associated with antigen processing, and Erp57 may allow for the understanding of the biochemistry of physiologic MHC1 folding in the ER. The use of mutant ␤2m molecules in these studies could help define the roles of various chaperones in transitional steps between ␤2m binding and complete MHC1 folding. The transfection of ␤2m mutant genes into mammalian cells could supply information on the relevance of the ␤2m-␣3 interaction to the complete MHC1 assembly process in the ER. However, even if the mutant ␤2m effects on folding are limited to extracel- 
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To assess the effect of the ␤2m mutant molecules on formation of stimulatory MHC1-antigenic peptide complexes, we tested their ability to block antigenic peptide and native ␤2m-mediated MHC1 folding at 37°C. The W60A mutant ␤2m molecules were able to block this folding. Because the mutants were also dominant negative for this antigenic peptide-mediated folding, we tested whether mutant ␤2m could block the functional response of a T-cell hybridoma specific for peptide-H-2D d complexes. At low peptide concentrations, W60A/D53K ␤2m was able to block the T-cell response. It was also of interest to assess the effects of these mutants on endogenously loaded antigenic peptides. Activation of a T-cell hybridoma by a transfectant cell line with endogenous peptide was more resistant to inhibition than cell lines loaded exogenously with peptide. If additional work supports a selective effect of mutant ␤2m on exogenous versus endogenous peptide loading, these mutants may be useful in defining whether there is a role for exogenous peptide loading in in vivo CTL-mediated responses and pathology. Mutants of ␤2m have also been generated that interfere with the binding of the non-TCR MHC1 ligands, Ly49A (58, 59 ) and CD8 (60) , to MHC1. Although the effects on CD8 binding were demonstrated with mutation of position 58 of ␤2m, mutation of position 60 also diminished CD8 binding to MHC1 (60) . However, the effects on MHC1 folding we observed with the W60A mutants are independent of CD8. In addition, the functional inhibition we observed of the B4.2.3 T-cell hybridoma cannot be explained by an effect on CD8 binding, because B4.2.3 does not express CD8. Different mutations of ␤2m between positions 52 and 63 have been generated (46) . Although the ability of these mutants to fold MHC1 expressed by peptide transport-deficient cells was not evaluated, some of these mutants interfered with the generation of a peptidespecific epitope in HLA-B27. There was only minimal blockade of CTL lysis by two of these mutants, and the blockade did not correlate with effects on the peptide-specific epitope. This suggests possible alternative effects of these mutant ␤2m molecules, such as antagonism of CD8 binding.
The folding of free MHC1 heavy chain on the surface of cells by ␤2m plays an important role in normal cells (55, 61, 62) , as well as in peptide transport-deficient cells. This folding can have immunologic consequences due to the enhanced presentation of exogenous peptide fragments to CTL (39, (63) (64) (65) . Such presentation of extracellularly processed (41, 66 -68) class I restricted peptides could cause lysis of uninfected bystander cells in a CTL response to virus. Understanding the mechanism of MHC1 folding and developing reagents that can interfere with this folding may suggest clinically relevant strategies to prevent such aberrant responses.
